Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Biodelivery Sciences International (MM) (BDSIW)

Biodelivery Sciences International (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BDSIW
DateTimeSourceHeadlineSymbolCompany
08/11/200514:44Business WireBDSI Announces Supply Agreement Relating to BEMA(TM) Fentanyl; Agreement with Aveva Drug Delivery Systems a Key Milestone as BDSNASDAQ:BDSIWBiodelivery Sciences International (MM)
01/11/200512:30Business WireBDSI Prepares For Phase III with BEMA(TM) Fentanyl Following Positive Results of Comparative Pharmacokinetic StudyNASDAQ:BDSIWBiodelivery Sciences International (MM)
05/10/200516:13Business WireBDSI Closes Public Offering of 4.4 Million SharesNASDAQ:BDSIWBiodelivery Sciences International (MM)
30/09/200513:04Business WireBDSI Prices Public Offering of 4.4 Million SharesNASDAQ:BDSIWBiodelivery Sciences International (MM)
30/09/200513:00Business WireBDSI Prices Public Offering of 4.4 Million SharesNASDAQ:BDSIWBiodelivery Sciences International (MM)
16/09/200521:30Business WireBDSI Announces Director Resignations; Donald Ferguson and Alan Pearce Resign So That Company Can Comply with Nasdaq IndependenceNASDAQ:BDSIWBiodelivery Sciences International (MM)
20/07/200515:28Business WireBDSI Announces Acceptance of Emezine(R) NDA for Review By FDANASDAQ:BDSIWBiodelivery Sciences International (MM)
18/07/200516:03Business WireBDSI Secures $7 Million Financing Commitment For Development of BEMA(TM) Fentanyl; Funding Targeted for Phase III Trials of CancNASDAQ:BDSIWBiodelivery Sciences International (MM)
03/06/200512:00Business WireBDSI Secures Additional $2.5 Million Financing With Laurus Master FundNASDAQ:BDSIWBiodelivery Sciences International (MM)
02/05/200512:30Business WireBDSI Announces Submission of NDA for Emezine; First Transmucosal Product for the Treatment of Nausea and VomitingNASDAQ:BDSIWBiodelivery Sciences International (MM)
12/11/200421:37PR Newswire (US)BDSI Reports Financial Results for the Third Quarter Ended September 30, 2004NASDAQ:BDSIWBiodelivery Sciences International (MM)
13/04/200417:00PR Newswire (US)BioDelivery Sciences International, Inc. Announces Licensing of Its Topical BioNasal (TM) Amphotericin B for Chronic SinusitisNASDAQ:BDSIW
06/04/200413:00PR Newswire (US)BioDelivery Sciences International, Inc. Reports 2003 ResultsNASDAQ:BDSIWBiodelivery Sciences International (MM)
 Showing the most relevant articles for your search:NASDAQ:BDSIW